Listen to the article
In a landmark year for federal fraud enforcement, the Department of Justice recovered a record $5.7 billion in healthcare fraud settlements under the False Claims Act (FCA) for fiscal year 2025, more than tripling the previous year’s total. This historic figure contributed to $6.8 billion in total judgments across all industries, the highest single-year recovery in the department’s history.
The settlements primarily involved fraud against federal healthcare programs including Medicare, Medicaid, and Tricare, which serves active and retired military service members and their families. Justice Department officials noted an expanded focus on enforcement in managed care, prescription drugs, and medically unnecessary treatments.
Under the False Claims Act, entities found liable for defrauding government programs can face severe financial penalties, including treble damages—three times the government’s damages—plus inflation-adjusted penalties. The law also permits private citizens to act as whistleblowers by filing lawsuits on the government’s behalf, receiving a portion of any resulting settlements.
In 2025, whistleblowers received more than $262 million for their roles in successful healthcare fraud lawsuits. The financial incentives appear to be driving increased participation, with a record 1,297 whistleblower cases filed last year, following the previous record of 980 cases in 2024.
Rachael Jones, principal at law firm McKool Smith and former deputy chief of the criminal division in the U.S. attorney general’s office in northern Texas, suggested that media coverage and social media awareness of settlements may be encouraging more whistleblowers to come forward.
“When you find out the marketing schemes of the pharmaceutical companies or that doctors are doing something that’s not in the best interest of the patient… The motivation to go after that is really high, because you can identify with the people,” Jones explained.
While healthcare has historically dominated FCA settlements due to growing federal health spending, the 2025 figures represent a remarkable increase from the $1.7 billion recovered in 2024. Many of the cases settled this year involve fraudulent activities that occurred more than a decade ago, reflecting the lengthy process of litigation and negotiation that typically precedes settlements.
Several major managed care companies faced significant penalties this year. New York-based Medicare Advantage insurer Independent Health agreed to pay up to $98 million to resolve allegations it submitted invalid diagnostic codes for reimbursement. Similarly, Seoul Medical Group, its subsidiary Advanced Medical Management, and its former president agreed to pay over $60 million for allegedly submitting false diagnostic codes for spinal conditions to increase Medicare Advantage payments.
In the pharmaceutical sector, CVS’s long-term care pharmacy services provider Omnicare settled for $949 million over allegations it dispensed medications to elderly and disabled residents in assisted living facilities without valid prescriptions. Drug manufacturer Teva Pharmaceuticals agreed to a $450 million settlement regarding claims of kickback schemes.
Legal experts anticipate that future FCA enforcement may increasingly target high-value drugs and procedures that represent the largest expenditures for federal healthcare programs. Novel treatments and pharmaceuticals could also face heightened scrutiny as the Justice Department continues its aggressive enforcement approach.
The record-breaking recoveries demonstrate the federal government’s intensified commitment to combating healthcare fraud and protecting the integrity of taxpayer-funded healthcare programs. With whistleblower participation at all-time highs and expanded enforcement priorities, healthcare providers and pharmaceutical companies can expect continued vigilance from federal authorities in the years ahead.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
8 Comments
This is certainly an eye-opening statistic. I wonder what factors contributed to this record-breaking year for healthcare fraud settlements – was it an increase in fraudulent activity, more effective detection, or a combination of both? Regardless, it’s good to see the government holding bad actors accountable.
That’s a great question. The article mentions an ‘expanded focus’ on certain areas, so it seems the DOJ may have ramped up its investigative efforts in those domains. But the underlying drivers are likely complex.
Wow, that’s a staggering amount recovered through FCA enforcement. It’s good to see the DOJ cracking down on healthcare fraud and protecting taxpayer funds. Curious to learn more about the key areas of focus – managed care, prescriptions, and unnecessary treatments.
Agreed, the scale of these settlements is quite remarkable. It will be interesting to see if this record year is part of a broader trend or a one-off spike.
This is a significant victory for the government’s crackdown on healthcare fraud. The record-breaking settlements underscore the scale of the problem and the importance of robust enforcement. I’m curious to see if this sets a new standard for future years.
You raise a good point. These types of enforcement actions can have a strong deterrent effect, which could drive down future fraud attempts.
Impressive that the DOJ was able to recover over $5.7 billion in healthcare fraud settlements. The False Claims Act seems to be an effective tool for incentivizing whistleblowers to come forward. It will be important to monitor how these funds are reinvested to improve program integrity.
The $5.7 billion in healthcare fraud settlements is certainly a sobering figure, but it’s encouraging to see the DOJ taking such strong action. Curious to understand more about the specific types of fraud that were uncovered and the impact on public programs like Medicare and Medicaid.